Literature DB >> 20628725

[Radiation therapy of lung carcinoma].

S Oertel1, J Debus, H Hof, M Bischof.   

Abstract

At first presentation and primary diagnosis approximately 50% of patients with non-small cell lung carcinoma (NSCLC) and 25% of patients with small cell lung carcinoma (SCLC) have a potentially curable tumor stage. Definitive, adjuvant and neoadjuvant radio- (chemo-)therapy play an important role as part of multimodal treatment approaches. High radiation doses can be achieved in tumor areas with modern radiotherapy planning and treatment techniques without an increase of side-effects. The 3 year overall survival after primary radiotherapy is approximately 50% for patients with NSCLC in stage I and 20% in stage IIIA. Radiotherapy can be used in patients with progressive metastatic disease after insufficient response to systemic therapy with threatening thoracic symptoms and for palliative treatment of cerebral, lymphatic and osseous metastases.

Entities:  

Mesh:

Year:  2010        PMID: 20628725     DOI: 10.1007/s00117-009-1957-1

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  26 in total

1.  A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

Authors:  S M Keller; S Adak; H Wagner; A Herskovic; R Komaki; B J Brooks; M C Perry; R B Livingston; D H Johnson
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).

Authors:  Ryosuke Tsuchiya; Kenji Suzuki; Yukito Ichinose; Yoh Watanabe; Tsutomu Yasumitsu; Naoki Ishizuka; Harubumi Kato
Journal:  J Thorac Cardiovasc Surg       Date:  2005-05       Impact factor: 5.209

Review 3.  Multimodality therapy for stage III non-small-cell lung cancer.

Authors:  Daniel Farray; Nena Mirkovic; Kathy S Albain
Journal:  J Clin Oncol       Date:  2005-05-10       Impact factor: 44.544

4.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database.

Authors:  Brian E Lally; Daniel Zelterman; Joseph M Colasanto; Bruce G Haffty; Frank C Detterbeck; Lynn D Wilson
Journal:  J Clin Oncol       Date:  2006-06-12       Impact factor: 44.544

6.  Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.

Authors:  Berend J Slotman; Murielle E Mauer; Andrew Bottomley; Corinne Faivre-Finn; Gijs W P M Kramer; Elaine M Rankin; Michael Snee; Matthew Hatton; Pieter E Postmus; Laurence Collette; Suresh Senan
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

7.  Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.

Authors:  Cécile Le Péchoux; Ariane Dunant; Suresh Senan; Aaron Wolfson; Elisabeth Quoix; Corinne Faivre-Finn; Tudor Ciuleanu; Rodrigo Arriagada; Richard Jones; Rinus Wanders; Delphine Lerouge; Agnès Laplanche
Journal:  Lancet Oncol       Date:  2009-04-20       Impact factor: 41.316

8.  Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients.

Authors:  R Arriagada; T Le Chevalier; A Rivière; P Chomy; I Monnet; E Bardet; J A Santos-Miranda; C Le Péhoux; M Tarayre; S Benhamou; A Laplanche
Journal:  Ann Oncol       Date:  2002-05       Impact factor: 32.976

9.  Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.

Authors:  Inga S Grills; Victor S Mangona; Robert Welsh; Gary Chmielewski; Erika McInerney; Shannon Martin; Jennifer Wloch; Hong Ye; Larry L Kestin
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

10.  [Assessment of cognitive function after preventive and therapeutic whole brain irradiation using neuropsychological testing].

Authors:  Susanne Penitzka; Sarah Steinvorth; Simone Sehlleier; Martin Fuss; Michael Wannenmacher; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2002-05       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.